Foresite Capital Fund IV, L.P. - 31 Dec 2024 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James Tananbaum
Security
Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol
LYEL
Shares outstanding
290,729,746 shares
Disclosed Ownership
19,478,893 shares
Ownership
6.7%
Form type
SCHEDULE 13G/A
Filing time
14 Feb 2025, 14:20:33 UTC
Date of event
31 Dec 2024
Next filing
15 May 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 2.9% 8,325,000 8,325,000 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 2.9% 8,325,000 8,325,000 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.8% 8,133,047 8,133,047 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.8% 8,133,047 8,133,047 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 1% 3,020,846 3,020,846 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 1% 3,020,846 3,020,846 0 /s/ James Tananbaum James Tananbaum, Managing Member
James Tananbaum 6.7% 19,478,893 19,478,893 0 /s/ James Tananbaum James Tananbaum